NCT00073918View on ClinicalTrials.gov

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

February 28, 1999

Primary Completion Date

October 2, 2011

Study Completion Date

October 2, 2011

Conditions
Anaplastic Large Cell LymphomaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaSplenic Marginal Zone LymphomaWaldenström Macroglobulinemia
Interventions
DRUG

cyclophosphamide

Given IV

DRUG

etoposide

Given IV

RADIATION

iodine I 131 tositumomab

Given IV

PROCEDURE

quality-of-life assessment

Ancillary study

PROCEDURE

peripheral blood stem cell transplantation

Undergo ASCT given via central catheter

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER